Skip to main content

Table 4 Treatment-emergent adverse events reported by at least 5% of patients treated with exenatide once weekly

From: Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes

Adverse event, n (%)

Overall (N = 1830)

Nausea

305 (16.7)

Diarrhea

207 (11.3)

Nasopharyngitis

152 (8.3)

Headache

145 (7.9)

Injection site nodule

141 (7.7)

Vomiting

128 (7.0)

Constipation

109 (6.0)

Injection site pruritus

101 (5.5)

 

All*

Severe †

Non-severe ‡

Hypoglycemia

317 (17.3)

  

  Background sulfonylurea use

230 (28.8)

0 (0.0)

104 (13.0)

  No background sulfonylurea use

86 (8.3)

1 (0.1)

23 (2.2)

  1. *All hypoglycemia: includes severe, non-severe, and symptoms of hypoglycemia (defined as any episode of hypoglycemia that does not meet severe or non-severe event criteria); †Severe hypoglycemia: symptoms resulting in loss of consciousness or seizure that showed prompt recovery after administration of glucose, or documented blood glucose <54 mg/dL that required third-party assistance because of severe impairment in consciousness or behavior; ‡Non-severe hypoglycemia: signs or symptoms of hypoglycemia accompanied by fingerstick blood glucose <54 mg/dL.